Marijuana Moment·5 Oct 2026
A request for information in the Federal Register seeks comment on four questions: which patients to study, dosing protocols with starting doses at or below 10 mg/kg, monitoring for cardiac and neurologic events, and ethical oversight including informed consent. Comments close on 20 November 2026. The agency says existing ibogaine research carries significant limitations and an uncertain benefit-risk profile, and it will not accept comments on legalization, scheduling or religious use.
Marijuana Moment·1 Oct 2026
The Psychedelics Advancing Therapies Caucus, co-chaired by Representatives Jack Bergman and Lou Correa, released a white paper synthesizing stakeholder input on psilocybin, ibogaine and DMT. It calls for federal guidelines, multiple credentialing pathways for providers, a national adverse-event monitoring system, insurance coverage, explicit protection for Indigenous and religious entheogenic practice, and guardrails against over-commercialization. Correa was careful to note that psychedelics are not a cure-all.
Marijuana Moment·30 Sep 2026
Ordinance 2026-186 passed unanimously, covering personal use, cultivation and non-commercial sharing of psilocybin mushrooms and ayahuasca. Peyote is explicitly excluded to protect the endangered plant and Native American religious practice. Commercial sales stay prohibited and impaired-driving and workplace rules are untouched, so this is about reducing fear of arrest rather than opening a market.
Psychedelic Alpha·2 Oct 2026
Editor Josh Hardman's quarterly review pulls together Definium's clinical readouts, federal regulatory meetings, academic research and the quarter's policy shifts, then sets out what to watch next. Worth bookmarking if you ever field questions from guests about what is legal, where, and on what evidence.